$4.030
+0.420 (+10.41%)At close
PMN Comparative Benchmarking
In the context of the broader market, PMN competes directly with industry leaders such as FLNA and ESLA. With a market capitalization of $36.15M, it holds a leading position in the sector. When comparing efficiency, PMN's gross margin of N/A stands against FLNA's N/A and ESLA's N/A. Such benchmarking helps identify whether ProMIS Neurosciences Inc is trading at a premium or discount relative to its financial performance.
ProMIS Neurosciences Inc Financial Performance
ProMIS has reported consistent losses, with net income reaching -11,729,656 USD in Q2 2026 and a forward P/E ratio of 0, indicating no earnings expected in the near term. The gross profit has been negative in recent quarters, reflecting ongoing financial challenges.
Financials
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.